Browsing by Author "Demirci, Umut"
Now showing items 1-6 of 6
-
Classic Kaposi's sarcoma: A review of 156 cases
Çetin, Bülent; Aktaş, Bilge; Bal, Öznur; Algın, Efnan; Akman, Tülay; Koral, Lokman; Kaplan, Mehmet Ali; Demirci, Umut; Uncu, Doğan; Özet, Ahmet (Elsevier Taiwan, 2018)Background: Kaposi's sarcoma (KS) is a reactive, multifocal, multicentric, angiogenic neoplastic proliferation that is thought to originate from endothelial cells that are infected with human herpesvirus-8 (HHV-8). This ... -
Clinical significance of lymph node ratio in locally advanced breast cancer molecular subtypes
Demircioğlu, Fatih; Demirci, Umut; Kılıç, Diclehan; Özkan, Seçil; Karahacıoğlu, Eray (Karger, 2013)Background: the ratio of metastatic to dissected lymph nodes (lymph node ratio; LNR) is a sensitive and superior prognostic factor for lymph node evaluation, but its relationship to cancer subtypes is unclear. Patients and ... -
Lymph node ratio assessment of brain metastasis in early breast cancer cases
Demircioğlu, Fatih; Demirci, Umut; Akmansu, Müge (Asian Pacific Organization for Cancer Prevention, 2013)Background: Ten to 30% of early breast cancer (EBC) patients develop brain metastasis (BM) during their follow-up. In this study, we aimed to evaluate importance of the lymph node ratio (LNR) in development of BM in EBC ... -
Pazopanib-induced hepatotoxicity in an experimental rat model
Çetin, Bülent; Yılmaz, Güldal Esendağlı; Armağan, Berkan; Afşar, Barış; Demirci, Umut; Gülbahar, Özlem; Gümüşsoy, Özge; Bilgetekin, İrem; Özet, Ahmet; Üner, Aytuğ (Karger, 2018)Pazopanib is an effective treatment for advanced renal cell carcinoma and soft tissue sarcoma. Besides classical adverse events of this drug class, hepatotoxicity has been described as a frequent side effect. the aim of ... -
Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish oncology group (TOG) study
Kahraman, Seda; Erul, Enes; Gümüşay, Özge; Güven, Deniz Can; Aksoy, Sercan; Başaran, Gül; Seyyar, Mustafa; Şahin, Elif; Çabuk, Devrim; Bayram, Ertuğrul; Paydaş, Semra; Demirel, Burçin Çakan; Yaren, Arzu; Gülbağcı, Burcu; Hacıbekiroğlu, İlhan; Baytemur, Naziyet Köse; Demirci, Umut; Davarcı, Sena Ece; Demir, Hacer; Mocan, Eda Eylemer; Doğan, Özlem; Çılbır, Ebru; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Kayıkcıoğlu, Erkan; Çetin, Bülent; Acar, Ömer; Erdoğan, Atike Pınar; Keskinkılıç, Merve; Yavuzşen, Tuğba; Ünal, Olcun Ümit; Yılmaz, Funda; Doğan, Mutlu; Orhan, Sibel Oyucu; Çubukcu, Erdem; Erol, Cihan; Sakalar, Teoman; Dulgar, Özgecan; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Isık, Deniz; Karaoğlanoğlu, Müge; Okutur, Sadi Kerem; Yıldırım, Nilgün; Aydın, Esra; Uluç, Başak Oyan; Keser, Murat; Bilgin, Burak; Aksoy, Asude; Eren, Önder; Kalkan, Nurhan Önal; Er, Muhammed Muhiddin; Yücel, Hakan; Sunar, Veli; Paksoy, Nail; Aydın, Dinçer; Turhal, Nazım Serdar; Menekşe, Serkan (Elsevier, 2025)Background: Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in the general population that is not limited by selection criteria in clinical studies. The aim of ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Demirel, Burçin Çakan; Acar, Ömer; Aksoy, Sercan; Baytemur, Nazife Köse; Şahin, Elif; Çabuk, Devrim; Başaran, Gül; Paydaş, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Gülbağcı, Mutlu; Paksoy, Nail; Davarcı, Sena Ece; Yılmaz, Funda; Doğan, Özlem; Orhan, Sibel Oyucu; Kayıkcıoğlu, Erkan; Aytaç, Ali; Keskinkılıç, Merve; Moçan, Eda Eylemer; Ünal, Ölçün Ümit; Aydın,Esra; Yücel, Hakan; Işık, Deniz; Eren, Önder; Uluç, Başak Oyan; Özçelik, Melike; Hacıbekiroğlu, İlhan; Aydıner, Adnan; Demir, Hacer; Öksüzoğlu, Berna; Çılbır, Ebru; Çubukçu, Erdem; Çetin, Bülent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yıldırım, Nilgün; Alkan, Ali; Selçukbiricik, Fatih; Aksoy, Asude; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tuğba; Aykan, Musa Barış; İnal, Ali; İriağaç, Yakup; Kalkan, Nurhan Önal; Keser, Murat; Sakalar, Teoman; Menekşe, Serkan; Kut, Engin; Bilgin, Burak; Karaoğlanoğlu, Müge; Sunar, Veli; Özdemir, Özlem; Turhal, Nazım Serdar; Karadurmuş, Nuri; Yalçın, Bülent; Şendur, Mehmet Ali Nahit (Future Medicine Ltd, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...
